Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study

Headache

Volumn 40, Issue 3, 2000, Pages 231-236

  Freund, Brian J ^a   Schwartz, Marvin ^a  

^a NONE

Author keywords

Botulinum toxin; Cervicogenic; Headache

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE; MALE; MUSCLE RELAXATION; NECK INJURY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRAPEZIUS MUSCLE; WHIPLASH INJURY;

ADULT; AGED; BOTULINUM TOXIN TYPE A; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HEADACHE DISORDERS; HUMANS; MALE; MIDDLE AGED; NECK; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; PILOT PROJECTS; RANGE OF MOTION, ARTICULAR;

EID: 0034122912     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2000.00033.x     Document Type: Article

References (43)

1. Leonardi M, Mussico M, Nappi G. Headache as a major public health problem: current status. Cephalalgia. 1998;18(suppl 21):66-69.
2. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol. 1991;44:1147-1157.
3. Nilsson N. The prevalence of cervicogenic headache in a random population sample of 20-59 year olds. Spine. 1995;20:1884-1888.
4. Lipchik GL, Holroyd KA, France CR, et al. Central and peripheral mechanisms in chronic tension-type headache. Pain. 1996;64:467-475.
5. Jensen R, Bendtsen L, Olesen J. Muscular factors are of importance in tension-type headache. Headache. 1998;38:10-17.
6. Pollmann W, Keidel M, Pfaffenrath V. Headache and the cervical spine: a critical review. Cephalalgia. 1997;17:801-816.
7. Sjaastad O, Fredriksen TA, Pfaffenrath V. Cervicogenic headache: diagnostic criteria. Headache. 1998; 38:442-445.
8. Hobson DE, Gladish DF. Botulinum toxin injection for cervicogenic headache. Headache. 1997;37:253-255.
9. Spitzer WO, Skovron ML, Salmi LR, et al. Scientific monograph of the Quebec Task Force on Whiplash-Associated Disorders: redefining "whiplash" and its management. Spine. 1995;20(suppl):12S-39S, erratum 2372.
10. Zwart JA. Neck mobility in different headache disorders. Headache. 1997;37:6-11.
11. Jaeger B. Are "cervicogenic" headaches due to myofascial pain and cervical spine dysfunction? Cephalalgia. 1989;9:157-164.
12. Pfaffenrath V, Dandekar R, Pollmann W. Cervicogenic headache - the clinical picture, radiological findings and hypotheses on its pathophysiology. Headache. 1987;27:495-499.
13. Bansevicius D, Sjaastad O. Cervicogenic headache: the influence of mental load on pain level and EMG of shoulder-neck and facial muscles. Headache. 1996;36:372-378.
14. Pikoff H. Is the muscular model of headache still viable? A review of conflicting data. Headache. 1984; 24:186-198.
15. Sessle BJ. Masticatory muscle disorders: basic science perspectives. In: Sessle BJ, Bryant PS, Dionne RA, eds. Progress in Pain Research and Management. Temporomandibular Disorders and Related Pain Conditions. IV. Seattle, Wash: International Association for the Study of Pain: 1995:47-61.
16. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain. 1993;54:241-289.
17. Relja M. Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol. 1997; 4(suppl 2):71-73.
18. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155-188.
19. Drachman AB. Atrophy of skeletal muscle in chick embryos treated with botulinum toxin. Science. 1964; 14:719-721.
20. Melling J, Hambleton P, Shone CC. Clostridium botulinum toxins: nature and preparation for clinical use. Eye. 1988;2:16-23.
21. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113:400-404.
22. Holds JB, Alderson K, Fogg SG, Anderson RL. Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Ophthalmol Vis Sci. 1990;31:964-967.
23. Jankovic J. Blepharospasm with basal ganglia lesions. Arch Neurol. 1986;43:866-868.
24. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044-1049.
25. Magoon EH. Chemodenervation of strabismic children. A 2-to 5-year follow-up study compared with shorter follow-up. Ophthalmology. 1989;96:931-934.
26. Jankovic J, Fahn S. Dystonic syndromes. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Baltimore: Urban & Schwarzenberg; 1988:283-314.
27. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616-623.
28. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. In: Transactions of the American Laryngological Association; April 1-2, 1989; San Francisco, Calif.
29. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol. 1989;98:93-97.
30. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53: 633-639.
31. Han SC, Harrison P. Myofascial pain syndrome and trigger-point management. Reg Anesth. 1997;22:89-101.
32. Freund BJ, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorder: preliminary findings. J Oral Maxillofac Surg. 1999;57:916-921.
33. Watanabe Y, Bakheit AM, McLellan DL. A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. Disabil Rehabil. 1998;20:62-65.
34. Freund BJ, Schwartz M. The use of botulinum toxin for the treatment of temporomandibular disorder: a pilot study. Oral Health. 1998;88:32-37.
35. Sessle BJ. Neural mechanisms and neuroplasticity related to deep craniofacial pain. Pain Forum. 1997; 6:173-175.
36. Svenson P. Pain mechanisms in myogenous temporomandibular disorders. Pain Forum. 1997;6:158-165.
37. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain. 1993;54:241-289.
38. Sessle BJ. Biological and psychological aspects of orofacial pain. In: Stohler CS, Carlson DS, eds. Craniofacial Growth Series 29, Center for Human Growth & Development. Ann Arbor: The University of Michigan: 1994:1-33.
39. Hylden JL, Nahin RL, Traub RJ, Dubner R. Expansion of receptive fields of spinal lamina 1 projection neurons in rats with unilateral adjuvant-induced inflammation: the contribution of dorsal horn mechanisms. Pain. 1989;37:229-243.
40. Kerr FW, Olafson RA. Trigeminal and cervical volleys. Convergence on single units in the spinal grey at C1 and C2. Arch Neurol. 1961;5:171-178.
41. Kerr FW. Central relationships of trigeminal and cervical primary afferents in the spinal cord and medulla. Brain Res. 1972;43:561-572.
42. Bogduk N. Headaches and the cervical spine. Cephalalgia. 1984;4:7-8.
43. Johnstone SJ, Adler CH. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm. Headache. 1998;38:366-368.